Brought to you by 
DiaKine develops Cell Therapeutics' LSF for diabetes
26 Feb 2007
Executive Summary
Cancer drug company Cell Therapeutics licensed to DiaKine (spun out from the University of Virginia School of Medicine in 2004 to develop diabetes therapies) patents and other IP rights related to lisofylline (LSF), a synthetic immunomodulator with anti-inflammatory properties. The rights allow DiaKine to develop the molecule to treat diabetes and related conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DiaKine develops Cell Therapeutics' LSF for diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice